Genetic Analysis AsFWB: 8V8

Genetic Analysis: Q2 2025 delivered strong sales growth, positive EBITDA, and strategic expansion in key markets

· Issued by Genetic Analysis AS

Q2 2025 saw 34% sales growth year-over-year, a positive EBITDA, and a narrowed net loss, driven by strong US sales and new product launches. Capital raises strengthened the balance sheet, while new partnerships and product launches in China and the US support future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Genetic Analysis As

All Genetic Analysis As news releases